Company Announcement / Press release Archives - Page 8 of 18

Xspray Pharma publishes Q4 Year-End report 2021

”When looking back at Xspray Pharma’s fourth quarter 2021, I see it marked by hope for the future. After the end of the quarter, we reached a significant milestone when the US Food and Drug Administration (FDA) announced that it had agreed to review Xspray Pharma’s first product candidate: Dasynoc, an improved version of dasatinib. […]

Xspray Pharma appoints Global Head of Marketing and Sales

Xspray Pharma AB (publ), (Nasdaq Stockholm: XSPRAY) announced today that the company has hired Anna-Karin Ekberg as Global Head of Marketing and Sales. She will take office in mid-March 2022. “At the beginning of the year, Xspray Pharma reached a substantial milestone when the FDA accepted to review our first product. This means that we are getting […]

FDA allows review of application for market approval for Xspray Pharma’s Dasynoc™

Xspray Pharma (publ) (Nasdaq Stockholm: XSPRAY) announced today that the US Food and Drug Administration (FDA) has agreed to review the company’s application for market approval for Xspray Pharma’s product candidate, Dasynoc™ (dasatinib) in the US under the 505(b)(2) process. In November 2021, Xspray Pharma submitted an application for market approval in the US of […]

Number of shares and votes in Xspray Pharma

Xspray Pharma AB (Nasdaq Stockholm: XSPRAY) announces today that the number of shares and votes in Xspray Pharma AB has changed as a result of shares being registered due to the directed share issue which was carried out in November 2021. Through the direct share issue, carried out in November 2021, the number of outstanding […]

Xspray Pharma submits application for market approval to FDA for its product candidate Dasynoc

Xspray Pharma (publ) (Nasdaq Stockholm: XSPRAY) announces today that the application for US market approval of its first product candidate Dasynoc (dasatinib) has been submitted, in accordance with plans, to the Food and Drug Administration (FDA) under the 505(b)(2) NDA procedure, which is the registration path that applies to improved drugs. The application consists of […]

Xspray Pharma strengthens the organization with IR and Communications function

Xspray Pharma AB (publ) (Nasdaq Stockholm: XSPRAY) today announces that the company is strengthening its organization by creating an Investor Relations and Communications function. Christina Malmberg Hägerstrand has been appointed Vice President and Head of Investor Relations and Communications, she joins Xspray Pharma in January 2022. “With the development of Xspray Pharma and the initial […]

Xspray Pharma completes a directed new share issue to Flerie Invest, raising approximately SEK 100 million

Xspray Pharma AB (publ) (Nasdaq Stockholm: XSPRAY) today announces that the board of directors has resolved on a directed new share issue of 1,612,904 shares at a price of SEK 62 per share, corresponding to in total approximately SEK 100 million. The board of directors of Xspray Pharma has, based on the authorisation granted by […]

Xspray Pharma publishes interim report Q3, January – September 2021

"Since the company's start, the business's focus and communication has been on generic and improved versions of PKIs. Going forward we have, after the end of the reporting period, decided to focus entirely on improved PKIs. In recent years, the value of generics in our models has gradually decreased, while the value of improved drugs […]

Xspray Pharma brings forward publication of the Q3 interim report

Xspray Pharma (publ) announces that the company is bringing forward the publication of its interim report for January-September, 2021, to Tuesday, October 26, 2021, instead of on Friday, November 4, 2021, as previously announced. The work with the quarterly accounts has proceeded faster than expected, therefore the Q3 interim report will be released earlier than […]

Xspray Pharma’s Nomination Committee for the Annual General Meeting 2022

Xspray Pharma AB (Nasdaq Stockholm: XSPRAY) publishes the Nomination Committee’s composition for the Annual General Meeting in 2022. The Nomination Committee, which has been appointed in accordance with the principles adopted by the Annual General Meeting on 20 May 2021, consists of: Gillis Cullin, appointed by Östersjöstiftelsen Anders Bladh, appointed by Ribbskottet AB Caroline Sjösten, […]